With multiple companies looking to address treatment shortcomings in chronic spontaneous urticaria (CSU) with standard of care Xolair, Celldex Therapeutics, Inc. presented Phase II data at the American Academy of Allergy, Asthma and Immunology annual meeting on 25 February that some analysts said suggest a best-in-class profile for the disease. Celldex is planning to take its drug, barzolvolimab, a binder of receptor tyrosine kinase KIT, into Phase III for CSU later this year, while awaiting 52-week data from the Phase II study.
Key Takeaways
-
In presentations at the AAAI meeting, Celldex and Sanofi both unveiled Phase II data for candidates that might offer efficacy in chronic spontaneous urticaria for patients whose disease is uncontrolled on Xolair.
Meanwhile, Sanofi, months after a US Food and Drug Administration complete response letter delayed its effort to add CSU...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
